Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome II Combo in Borderline Resectable Pancreatic Cancer
NCT06387810Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in pancreatic cancer (PC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Event Free Survival at 5 years. Started Apr 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06387810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387810.